Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine 60 mg versus 120 mg in hospitalized adults with severe major depressive disorder
2006-001618-34Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of duloxetine in major depressive disorder (MDD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change in MADRS total score from baseline to week 4. Started Jul 2007; status: completed.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2006-001618-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001618-34.